Insights from the CTOS Annual Meeting

Quiz: Which SOC Treatment is an Alternative for Imatinib Intolerant Advanced, mGIST?

11/16/2021

Approved globally, _______ is established as the standard-of-care second line for the treatment of advanced and/or metastatic gastrointestinal stromal tumor patients after failure or intolerance to imatinib.

Approved globally, _______ is...

11/16/2021

Oncology

Sunitinib Displays Safety, Efficacy for Imatinib-Resitant Patients with Advanced GIST

11/15/2021

A real-world study confirms sunitinib is found as a safe and effective option for the treatment of imatinib-resistant, advanced GIST patients.

A real-world study confirms...

11/15/2021

Oncology

Imatinib Exhibits Viability as Neoadjuvant Therapy for GIST

11/15/2021

Imatinib is found feasible as neoadjuvant therapy for GIST, with the potential of to tumor size reduction and high morbidity prevention, according to data presented at the 2021 CTOS Annual Meeting.

Imatinib is found feasible as...

11/15/2021

Oncology

Conference Coverage

Dose Escalation of Ripretinib Yields OR in Tumor Progressive GIST

11/15/2021

Investigators sought to evaluate the tolerability and response of patients with GIST treated outside clinical trials with ripretinib dose escalation, presented at the 2021 CTOS Annual Meeting.

Investigators sought to evaluate...

11/15/2021

Oncology

Insights from the CTOS Annual Meeting

Tracks

Specialties

Events

Year Round Education

HMP Global Products